trending Market Intelligence /marketintelligence/en/news-insights/trending/OfXlkOpHzVXzFTr1GZOa0w2 content esgSubNav
In This List

Dechra to acquire minority stake in Medical Ethics

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Dechra to acquire minority stake in Medical Ethics

Dechra Pharmaceuticals PLC entered an A$18.0 million deal to acquire 33% of Medical Ethics Pty Ltd.

Medical Ethics is the parent company of Animal Ethics Pty. Ltd., which has sold the rights of its Tri-Solfen treatment to Dechra Pharmaceuticals for all regions except Australia and New Zealand.

Dechra will have a seat on the Medical Ethics board and minority shareholder rights.

Tri-Solfen is a painkiller used during routine treatments of farm animals such as castration, tail docking, debudding and dehorning.

As of March 30, US$1 was equivalent to A$1.30.